COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF
Aspects described herein relate to compositions, including edible compositions, infused with nicotine compounds and methods of use for the treatment of a nicotine-related disorders. More particularly, aspects described herein relate to compositions, including edible compositions, infused with nicotine compounds that provide enhanced bioavailability of the nicotine compounds in a subject, and that mask unpleasant tastes of the nicotine compounds.
1 .- 65 . (canceled)
66 . A composition, comprising:
a) a therapeutically effective amount of nicotine, a nicotine derivative, or a salt thereof;
b) a bioavailability enhancing agent comprising an edible oil; and
c) an edible substrate.
67 . The composition according to claim 66 , wherein the composition comprises nicotine.
68 . The composition according to claim 66 , wherein the nicotine derivative is selected from the group consisting of nicotine bitartrate, lobeline, cytisine, nicotine polacrilex, nornicotine, nicotine 1-N-oxide, metanicotine, nicotine imine, nicotine N-glucuronide, N-methylnicotinium, N-n-decylnicotinium, 5′-cyanonicotine, 3,4-dihydrometanicotine, N′-methylnicotinium, N-octanoylnornicotine, 2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo(3,2-h)isoquinoline, 5-isothiocyanonicotine, 5-iodonicotine, 5′-hydroxycotinine-N-oxide, homoazanicotine, nicotine monomethiodide, N-4-azido-2-nitrophenylnornicotine, N-methylnornicotinium, nicotinium molybdophosphate resin, N-methyl-N′-oxonicotinium, N′-propylnornicotine, pseudooxynicotine, 4′-methylnicotine, 5-fluoronicotine, K(s-nic)5(Ga2(N,N′-bis-(2,3-dihydroxybenzoyl)-1,4-phenylenediamine)3), 5-methoxynicotine, 1-benzyl-4-phenylnicotinamidinium, 6-n-propylnicotine, SIB1663, 6-hydroxynicotine, N-methyl-nicotine, 6-(2-phenylethyl)nicotine, N′-formylnornicotine, N-n-octylnicotinium, N-(n-oct-3-enyl)nicotinium, N-(n-dec-9-enyl)nicotinium, 5′-acetoxy-N′-nitrosonornicotine, 4-hydroxynicotine, 4-(dimethylphenylsilyl)nicotine, N′-carbomethoxynornicotine, and N-methylnicoton.
69 . The composition according to claim 66 , comprising nicotine hydrogen tartrate, nicotine bitartrate dihydrate, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulfate, nicotine citrate, nicotine zinc chloride monohydrate, nicotine salicylate, nicotine oil, or nicotine complexed with cyclodextrin.
70 . The composition according to claim 66 , wherein the nicotine derivative is an agonist having selectivity to an α 7 nicotinic receptor subtype, wherein the α 7 nicotinic receptor subtype agonist is selected from the group consisting of N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide, (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2′,3′:5,6]pyrano[2,3-d]azepine, 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]-pyridine, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole, (5 S)-spiro[1,3-oxazolidine-5,8′-1-azabicyclo[2.2.2]octane]-2-one, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide, 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide, EVP-6124, EVP-4473, TC-6987, and MEM3454, or the nicotine derivative is an agonist having selectivity to an α 4 β 2 nicotinic receptor subtype, wherein the α 4 β 2 nicotinic receptor subtype agonist is selected from the group consisting of 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3) benzazepine, (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine, [3-(2(S))-azetidinylmethoxy)71 pyridine] dihydrochloride, (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido [2′,3′:5,6]pyrano[2,3-d]azepine, A-969933, S35836-1, S35678-1, and 3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane.
71 . The composition according to claim 66 , wherein the bioavailability enhancing agent bioavailability enhancing agent is a protective colloid, an edible oil or fat.
72 . The composition according to claim 71 , wherein the edible oil is coconut oil, peanut oil, soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, or sunflower seed oil.
73 . The composition according to claim 72 , wherein the edible oil comprises fatty acids selected from the group consisting of oleic acid, undecanoic acid, valeric acid, heptanoic acid, pelargonic acid, capric acid, lauric acid, and eicosapentaenoic acid.
74 . The composition according to claim 66 , wherein the edible substrate is selected from the group consisting of inulin, starch, modified starches, xanthan gum, carboxymethyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, konjac, chitosan, tragacanth, karaya, ghatti, larch, carageenan, alginate, chemically modified alginate, agar, guar, locust bean, psyllium , tara, gellan, curdlan, pullan, gum arabic, gelatin, pectin, and combinations thereof.
75 . The composition according to claim 66 , wherein the edible substrate is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.
76 . The composition according to claim 66 , further comprising a flavoring agent selected from the group consisting of vanilla, vanillin, ethyl vanillin, orange oil, fruit and berry type flavorants, dramboui, bourbon, scotch, whiskey, spearmint, lavender, cinnamon, chai, cardamon, apium graveolents, clove, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, lemon oil, Japanese mint, cassia , caraway, cognac, jasmin, chamomile, menthol, ylang ylang, sage, fennel, pimenta, ginger, anise, chai, coriander, coffee, peppermint, wintergreen, mint oils from a species of the genus Mentha , and combinations thereof.
77 . The composition according to claim 66 , further comprising an additive selected from the group consisting of a non-nicotine alkaloid, a mineral, a vitamin, a dietary supplement, a dietary mineral, a nutraceutical, an energizing agent, a soothing agent, a coloring agent, an amino acid, a chemesthetic agent, an antioxidant, a food grade emulsifier, a pH modifier, a botanical, a teeth whitening agent, a therapeutic agent, a sweetener, a flavorant, and combinations thereof.
78 . A process for preparing an edible product infused with nicotine, a nicotine derivative, or a salt thereof, comprising:
a) providing a therapeutically effective amount of a nicotine compound;
b) providing a bioavailability enhancing agent, wherein the bioavailability agent comprises an edible oil;
c) providing an edible substrate;
d) contacting the edible substrate with the edible oil, nicotine compound and bioavailability enhancing agent to form an infused edible substrate; and
e) dehydrating the edible substrate.
79 . The process according to claim 78 , wherein the process comprises nicotine.
80 . The process according to claim 78 , comprising nicotine hydrogen tartrate, nicotine bitartrate dihydrate, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulfate, nicotine citrate, nicotine zinc chloride monohydrate, nicotine salicylate, nicotine oil, or nicotine complexed with cyclodextrin.
81 . The process according to claim 78 , wherein the nicotine derivative is an agonist having selectivity to an α7 nicotinic receptor subtype, wherein the α7 nicotinic receptor subtype agonist is selected from the group consisting of N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide, (5aS,8 S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2′,3′:5,6]pyrano[2,3-d]azepine, 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]-pyridine, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole, (5S)-spiro[1,3-oxazolidine-5,8′-1-azabicyclo[2.2.2]octane]-2-one, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide, 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide, EVP-6124, EVP-4473, TC-6987, and MEM3454, or the nicotine derivative is an agonist having selectivity to an α 4 β 2 nicotinic receptor subtype, wherein the α 4 β 2 nicotinic receptor subtype agonist is selected from the group consisting of 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3) benzazepine, (2 S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine, [3-(2(S))-azetidinylmethoxy)pyridine] dihydrochloride, (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido [2′,3′:5,6]pyrano[2,3-d]azepine, A-969933, S35836-1, S35678-1, and 3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane.
82 . The process according to claim 78 , wherein the bioavailability enhancing agent bioavailability enhancing agent is a protective colloid, an edible oil or fat.
83 . The process according to claim 82 , wherein the edible oil is coconut oil, peanut oil, soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, or sunflower seed oil.
84 . The process according to claim 83 , wherein the edible oil comprises fatty acids selected from the group consisting of oleic acid, undecanoic acid, valeric acid, heptanoic acid, pelargonic acid, capric acid, lauric acid, and eicosapentaenoic acid.
85 . The process according to claim 78 , wherein the edible substrate is selected from the group consisting of inulin, starch, modified starches, xanthan gum, carboxymethyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, konjac, chitosan, tragacanth, karaya, ghatti, larch, carageenan, alginate, chemically modified alginate, agar, guar, locust bean, psyllium , tara, gellan, curdlan, pullan, gum arabic, gelatin, pectin, and combinations thereof.
86 . The process according to claim 78 , wherein the edible substrate is selected from the group consisting of tea leaves, coffee beans, cocoa powder, meats, fish, fruits, vegetables, dairy products, legumes, pastas, breads, grains, seeds, nuts, spices, and herbs.
87 . A process for preparing a beverage product infused with nicotine, a nicotine derivative, or a salt thereof, obtainable by the steps of:
a) providing a composition according to claim 66 wherein the edible substrate is tea leaves, coffee beans, or cocoa powder;
b) dehydrating the composition; and
c) steeping the composition in a liquid;
thereby producing the beverage product infused with the nicotine compound.
88 . The process according to claim 87 , wherein the beverage product comprises nicotine.
89 . The process according to claim 87 , comprising nicotine hydrogen tartrate, nicotine bitartrate dihydrate, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulfate, nicotine citrate, nicotine zinc chloride monohydrate, nicotine salicylate, nicotine oil, or nicotine complexed with cyclodextrin.
90 . The process according to claim 87 , wherein the nicotine derivative is an agonist having selectivity to an α 7 nicotinic receptor subtype, wherein the α 7 nicotinic receptor subtype agonist is selected from the group consisting of N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide, (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2′,3′:5,6]pyrano[2,3-d]azepine, 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]-pyridine, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole, (5S)-spiro[1,3-oxazolidine-5,8′-1-azabicyclo[2.2.2]octane]-2-one, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide, 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide, EVP-6124, EVP-4473, TC-6987, and MEM3454, or the nicotine derivative is an agonist having selectivity to an α 4 β 2 nicotinic receptor subtype, wherein the α 4 β 2 nicotinic receptor subtype agonist is selected from the group consisting of 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3) benzazepine, (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine, [3-(2(S))-azetidinylmethoxy)pyridine] dihydrochloride, (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido [2′,3′:5,6]pyrano[2,3-d]azepine, A-969933, S35836-1, S35678-1, and 3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane.
91 . The process according to claim 87 , wherein the bioavailability enhancing agent bioavailability enhancing agent is a protective colloid, an edible oil or fat.
92 . The process according to claim 91 , wherein the edible oil is coconut oil, peanut oil, soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, or sunflower seed oil.
93 . The composition according to claim 92 , wherein the edible oil comprises fatty acids selected from the group consisting of oleic acid, undecanoic acid, valeric acid, heptanoic acid, pelargonic acid, capric acid, lauric acid, and eicosapentaenoic acid.
94 . The composition according to claim 87 , further comprising a flavoring agent selected from the group consisting of vanilla, vanillin, ethyl vanillin, orange oil, fruit and berry type flavorants, Dramboui, bourbon, scotch, whiskey, spearmint, lavender, cinnamon, chai, cardamon, apium graveolents, clove, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, lemon oil, Japanese mint, cassia , caraway, cognac, jasmin, chamomile, menthol, ylang ylang, sage, fennel, pimenta, ginger, anise, chai, coriander, coffee, peppermint, wintergreen, mint oils from a species of the genus Mentha , and combinations thereof.
95 . The composition according to claim 87 , further comprising an additive selected from the group consisting of a non-nicotine alkaloid, a mineral, a vitamin, a dietary supplement, a dietary mineral, a nutraceutical, an energizing agent, a soothing agent, a coloring agent, an amino acid, a chemesthetic agent, an antioxidant, a food grade emulsifier, a pH modifier, a botanical, a teeth whitening agent, a therapeutic agent, a sweetener, a flavorant, and combinations thereof.